OpGen (NASDAQ:OPGN) Now Covered by StockNews.com

StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN) in a report issued on Thursday morning. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Price Performance

OPGN opened at $1.38 on Thursday. The business’s 50-day moving average price is $1.02 and its two-hundred day moving average price is $1.61. OpGen has a 1 year low of $0.53 and a 1 year high of $9.90.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.